EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis

Chiara Dalle Fratte iD, Jerry Polesel iD, Sara Gagno, Bianca Posocco, Elena De Mattia iD, Rossana Roncato iD, Marco Orleni iD, Fabio Puglisi iD, Michela Guardascione iD, Angela Buonadonna iD, Giuseppe Toffoli iD, Erika Cecchin iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24043303 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Chiara Dalle Fratte und 11 weiteren Autor:innen. Beteiligte Einrichtung: Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. Hauptthemen laut MEDLINE: Antineoplastic Agents, Gastrointestinal Stromal Tumors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Community's Horizon 2020 Programme (Ubiquitous Pharmacogenomics - UPGx), Italian Ministry of Health (Ricerca Corrente).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adequate imatinib plasma levels are necessary to guarantee an efficacious and safe treatment in gastrointestinal stromal tumor (GIST) and chronic myeloid leukemia (CML) patients. Imatinib is a substrate of the drug transporters ATP-binding cassette subfamily B member 1 (ABCB1) and ATP-binding cassette subfamily G member 2 (ABCG2) that can affect its plasma concentration. In the present study, the association between three genetic polymorphisms in ABCB1 (rs1045642, rs2032582, rs1128503) and one in ABCG2 (rs2231142) and the imatinib plasma trough concentration (Ctrough) was investigated in 33 GIST patients enrolled in a prospective clinical trial. The results of the study were meta-analyzed with those of other seven studies (including a total of 649 patients) selected from the literature through a systematic review process. The ABCG2 c.421C>A genotype demonstrated, in our cohort of patients, a borderline association with imatinib plasma trough levels that became significant in the meta-analysis. Specifically, homozygous carriers of the ABCG2 c.421 A allele showed higher imatinib plasma Ctrough with respect to the CC/CA carriers (Ctrough, 1463.2 ng/mL AA, vs. 1196.6 ng/mL CC + AC, p = 0.04) in 293 patients eligible for the evaluation of this polymorphism in the meta-analysis. The results remained significant under the additive model. No significant association could be described between ABCB1 polymorphisms and imatinib Ctrough, neither in our cohort nor in the meta-analysis. In conclusion, our results and the available literature studies sustain an association between ABCG2 c.421C>A and imatinib plasma Ctrough in GIST and CML patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsGastrointestinal Stromal TumorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansAdenosine TriphosphateATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily G, Member 2GenotypeImatinib MesylateNeoplasm ProteinsPolymorphism, Single NucleotideProspective Studies

Stichwörter der Autor:innen

ABCB1ABCG2CMLGISTimatinib mesylatepharmacogeneticstherapeutic drug monitoring

Substanzen

ABCB1 protein, humanABCG2 protein, humanAdenosine TriphosphateAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily G, Member 2Imatinib MesylateNeoplasm Proteins

Autor:innen und Institutionen

  • Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
  • Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
  • Doctoral School in Pharmacological Sciences, University of Padua, 35131 Padova, Italy.
  • Department of Medical Oncology, Unit of Medical Oncology and Cancer Prevention, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
  • Department of Medicine, University of Udine, 33100 Udine, Italy.

ORCID-Profile: Chiara Dalle Fratte, Jerry Polesel, Elena De Mattia, Rossana Roncato, Marco Orleni, Fabio Puglisi, Michela Guardascione, Angela Buonadonna, Giuseppe Toffoli, Erika Cecchin

Förderung

  • European Community's Horizon 2020 Programme (Ubiquitous Pharmacogenomics - UPGx)
  • Italian Ministry of Health (Ricerca Corrente)

Zitieren

APA

Dalle Fratte, C., Polesel, J., Gagno, S., Posocco, B., De Mattia, E., Roncato, R., Orleni, M., Puglisi, F., Guardascione, M., Buonadonna, A., Toffoli, G., & Cecchin, E. (2023). Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043303

Vancouver

Dalle Fratte C, Polesel J, Gagno S, Posocco B, De Mattia E, Roncato R, et al. Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043303

BibTeX
@article{DalleFratte2023,
  author = {Dalle Fratte, Chiara and Polesel, Jerry and Gagno, Sara and Posocco, Bianca and De Mattia, Elena and Roncato, Rossana and Orleni, Marco and Puglisi, Fabio and Guardascione, Michela and Buonadonna, Angela and Toffoli, Giuseppe and Cecchin, Erika},
  title = {Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24043303}
}
Kostenlos starten →